ALIMERA SCIENCES LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-04-17.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Figures converted to GBP from EUR at 0.870 per EUR (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +40.2%

  £13,269,397 → £18,606,618

• Cash

  +25.8%

  £942,138 → £1,184,741

• Net assets

  -68.5%

  -£20,587,270 → -£34,680,918

• Employees

  -3.3%

  30 → 29

• Operating profit

  -84.4%

  -£5,386,988 → -£9,935,229

• Profit before tax

  -47.8%

  -£10,272,402 → -£15,183,160

• Wages

  +46.6%

  £2,501,408 → £3,666,790

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Blick Rothenberg Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Notwithstanding the deficit on shareholders' funds, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. The company has also received a letter of financial support from the wider group. Accordingly, the directors continue to adopt the going concern basis in preparing the financial statements.”

Significant events

• “In 2021, Alimera Sciences Limited entered into a License Agreement with Ocumension Limited (Ocumension) in which Ocumension was granted an exclusive license for the development and commercialization of the 190 microgram fluocinolone acetonide intravitreal implant applicator for the treatment and prevention of eye diseases in humans, other than uveitis, in China, East Asia, and the Western Pacific”
• “The revenue increase of 40% is driven by increasing growth in direct sales and improving demand from our distribution partners. The loss realised is due to increased personnel, consultant costs & marketing costs and interest payable on promissory note with Alimera Sciences, Inc.”
• “Following the acquisition of the company by ANI Pharmaceuticals, Inc. all outstanding share options were settled, and the related share-based payment expense was accelerated.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.